Medical Director, University of Ottawa
Dr. Chakraborty is the Chair and Chief of Pediatrics at the University of Ottawa and the Children's Hospital of Eastern Ontario (CHEO) in Ottawa, Canada. He has a long history with the care of patients with Inherited Metabolic Diseases (IMD) and with leading population based Newborn Screening. He started as a clinician seeing patients with IMD in 2003, and was the Medical and Laboratory Director for Newborn Screening Ontario (NSO) from 2007-2023; NSO leads the newborn screening program for the Province of Ontario which screens about 145,000 babies annually. Since 2020, he has served as a Senior Medical Advisory for the Laboratories and Diagnostics Branch of the Ontario Ministry of Health, and chairs Ontario's Provincial Genetics Advisory Committee. Internationally, he is a member of the ClinGen pediatric actionability working group, was on the organizing committee of the 2020 Association of Public Health Laboratories newborn screening and genetic testing symposium, and served on the 2018 expert advisory panel reviewing the American federal recommended universal screening panel decision process. His undergraduate and postgraduate education took him on a tour of the province of Ontario. He completed his medical school at McMaster University in 1993, then specialized in Medical Biochemistry at Western University, Pediatrics at the University of Ottawa, and finally subspecialized in Biochemical Genetics at the University of Toronto. He joined CHEO in 2003 as a metabolic diseases physician, co-authored CHEO's proposal to modernize Ontario's newborn screening program in 2005 and led its move to Ottawa in 2006. His research is focused on the overlapping areas of improving outcomes for patients with inherited metabolic diseases, newborn screening, and metabolomics .Finally, he is a Principal Investigator and co-leads the CIHR-funded Canadian Inherited Metabolic Disease Research Network and INFORM-RARE project.